Research Articles
Research articles concerning NAFLD are extracted from PubMed. For each individual article, related therapeutic strategies, targets, drugs and associated diseases in NAFLDkb are presented with knowledge graphs.
stats1
stats2
stats3
stats4
Search for:
Ursodeoxycholic acid254 records.
| Article ID | PMID | Source | Title | Publish Year | |
|---|---|---|---|---|---|
| A00271 | 35159219 | Cells | S-Adenosylmethionine: From the Discovery of Its Inhibition of Tumorigenesis to Its Use as a Therapeutic Agent. | 2022 | Details |
| A00474 | 35068796 | J Clin Exp Hepatol | A Current Understanding of Bile Acids in Chronic Liver Disease. | 2021 | Details |
| A00594 | 35035690 | Am J Transl Res | Bile acid metabolism and liver fibrosis following treatment with bifid triple viable capsules in nonalcoholic fatty liver disease. | 2021 | Details |
| A00604 | 35033554 | Eur J Pharmacol | Ursodesoxycholic acid is an FFA4 agonist and reduces hepatic steatosis via FFA4 signaling. | 2022 | Details |
| A00760 | 34977519 | JHEP Rep | Pegbelfermin selectively reduces secondary bile acid concentrations in patients with non-alcoholic steatohepatitis. | 2021 | Details |
| A00896 | 34938193 | Front Pharmacol | Ursodeoxycholic Acid Treatment Restores Gut Microbiota and Alleviates Liver Inflammation in Non-Alcoholic Steatohepatitic Mouse Model. | 2021 | Details |
| A00941 | 34923459 | Wiad Lek | THE EFFECTIVENESS OF COMPLEX THERAPY WITH THE INCLUSION OF THE URSODEOXYCHOLIC ACID IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE IN COMBINATION WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE. | 2021 | Details |
| A01923 | 34560694 | Eur J Gastroenterol Hepatol | Healthcare practitioners' diagnostic and treatment practice patterns of nonalcoholic fatty liver disease in Poland: a cross-sectional survey. | 2022 | Details |
| A01996 | 34535644 | Nat Commun | A phase 2, proof of concept, randomised controlled trial of berberine ursodeoxycholate in patients with presumed non-alcoholic steatohepatitis and type 2 diabetes. | 2021 | Details |
| A02341 | 34411400 | Liver Int | Bile acid dysmetabolism in the gut-microbiota-liver axis under hepatitis C virus infection. | 2021 | Details |
| A03036 | 34156011 | Wiad Lek | THE EFFECT OF COMPREHENSIVE TREATMENT OF PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE IN COMBINATION WITH PREDIABETES ON THE LIPID PROFILE. | 2021 | Details |
| A03701 | 33898959 | JHEP Rep | Potent suppression of hydrophobic bile acids by aldafermin, an FGF19 analogue, across metabolic and cholestatic liver diseases. | 2021 | Details |
| A03905 | 33824248 | Korean J Gastroenterol | Efficacy and Safety of Biphenyl Dimethyl Dicarboxylate and Ursodeoxycholic Acid Combination in Chronic Hepatitis Related to Metabolic Syndrome Components. | 2021 | Details |
| A04051 | 33776366 | World J Gastroenterol | Ursodeoxycholic acid as a means of preventing atherosclerosis, steatosis and liver fibrosis in patients with nonalcoholic fatty liver disease. | 2021 | Details |
| A04068 | 33771699 | Pharmacol Res | Epigenetics in NAFLD/NASH: Targets and therapy. | 2021 | Details |
| A04072 | 33769703 | Physiol Rep | ω-Imidazolyl-alkyl derivatives as new preclinical drug candidates for treating non-alcoholic steatohepatitis. | 2021 | Details |
| A04120 | 33750416 | J Transl Med | LncRNA-Gm9795 promotes inflammation in non-alcoholic steatohepatitis via NF-[Formula: see text]B/JNK pathway by endoplasmic reticulum stress. | 2021 | Details |
| A04188 | 33722778 | Clin Res Hepatol Gastroenterol | Efficacy and safety of obeticholic acid in liver disease-A systematic review and meta-analysis. | 2021 | Details |
| A04443 | 33615207 | JHEP Rep | NASH-related increases in plasma bile acid levels depend on insulin resistance. | 2020 | Details |
| A05097 | 33377363 | Asia Pac J Clin Nutr | Efficacy of ursodeoxycholic acid in nonalcoholic fatty liver disease: An updated meta-analysis of randomized controlled trials. | 2020 | Details |
| A06217 | 32964201 | JHEP Rep | The Fatty Liver Assessment in Germany (FLAG) cohort study identifies large heterogeneity in NAFLD care. | 2020 | Details |
| A06984 | 32673798 | Mol Metab | Non-alcoholic fatty liver disease and steatohepatitis: State of the art on effective therapeutics based on the gold standard method for diagnosis. | 2020 | Details |
| A07046 | 32645206 | Cochrane Database Syst Rev | Bile acids for non-alcoholic fatty liver disease and/or steatohepatitis. | 2020 | Details |
| A07152 | 32598715 | Ter Arkh | [Evaluation of the effectiveness of differentiated therapy of non-alcoholic fatty liver disease]. | 2020 | Details |
| A07164 | 32595039 | Biochem Biophys Res Commun | Ursodeoxycholic acid alleviates nonalcoholic fatty liver disease by inhibiting apoptosis and improving autophagy via activating AMPK. | 2020 | Details |
| A07506 | 32467498 | Am J Ther | How to Reduce Cardiovascular Risk in Nonalcoholic Fatty Liver Disease. | 2020 | Details |
| A08004 | 32282030 | Br Med Bull | Obeticholic acid-a new therapy in PBC and NASH. | 2020 | Details |
| A08235 | 32191400 | Clin Pharmacol Drug Dev | Pharmacokinetics and Pharmacodynamics of Ursodeoxycholic Acid in an Overweight Population With Abnormal Liver Function. | 2020 | Details |
| A08890 | 31950811 | Acta Gastroenterol Belg | Impact of liver inflammation on whole body insulin resistance : a case report on primary biliary cholangitis. | 2020 | Details |
| A09955 | 31543686 | World J Gastroenterol | Value of controlled attenuation parameter in fibrosis prediction in nonalcoholic steatohepatitis. | 2019 | Details |
| A10168 | 31460584 | Arq Gastroenterol | N-ACETYLCYSTEINE AND/OR URSODEOXYCHOLIC ACID ASSOCIATED WITH METFORMIN IN NON-ALCOHOLIC STEATOHEPATITIS: AN OPEN-LABEL MULTICENTER RANDOMIZED CONTROLLED TRIAL. | 2019 | Details |
| A10338 | 31384531 | Acta Pharm Sin B | Ablation of gut microbiota alleviates obesity-induced hepatic steatosis and glucose intolerance by modulating bile acid metabolism in hamsters. | 2019 | Details |
| A10413 | 31345778 | Lancet Gastroenterol Hepatol | Norursodeoxycholic acid versus placebo in the treatment of non-alcoholic fatty liver disease: a double-blind, randomised, placebo-controlled, phase 2 dose-finding trial. | 2019 | Details |
| A10465 | 31325638 | Biochim Biophys Acta Mol Cell Biol Lipids | Ursodeoxycholic acid is a GPBAR1 agonist and resets liver/intestinal FXR signaling in a model of diet-induced dysbiosis and NASH. | 2019 | Details |
| A10487 | 31315327 | J Assoc Physicians India | Etiological Patterns, Liver Fibrosis Stages and Prescribing Patterns of Hepato-Protective Agents in Indian Patients with Chronic Liver Disease. | 2018 | Details |
| A10612 | 31271806 | Metabolism | Activation of G0/G1 switch gene 2 by endoplasmic reticulum stress enhances hepatic steatosis. | 2019 | Details |
| A10827 | 31170503 | Biochim Biophys Acta Mol Cell Biol Lipids | Turnover of bile acids in liver, serum and caecal content by high-fat diet feeding affects hepatic steatosis in rats. | 2019 | Details |
| A10961 | 31101782 | Georgian Med News | COMPARATIVE ANALYSIS OF EFFICIENCY OF URSODEOXYCHOLIC ACID AND COMBINATION OF VITAMIN E AND VITAMIN C IN TREATMENT OF NON-DIABETIC NONALCOHOLIC STEATOHEPATITIS. | 2019 | Details |
| A10978 | 31094181 | Ter Arkh | Non-alcoholic fatty liver disease as a cause and consequence of cardio-metabolic complications. Role of the ursodeoxicholic acid in the pharmacotherapy. | 2019 | Details |
| A11041 | 31071511 | Biomed Pharmacother | Therapeutic effects of curcumin and ursodexycholic acid on non-alcoholic fatty liver disease. | 2019 | Details |
| A11302 | 30948912 | World J Gastroenterol | Ursodeoxycholic acid ameliorates hepatic lipid metabolism in LO2 cells by regulating the AKT/mTOR/SREBP-1 signaling pathway. | 2019 | Details |
| A11464 | 30884843 | Cells | Ursodeoxycholic Acid Regulates Hepatic Energy Homeostasis and White Adipose Tissue Macrophages Polarization in Leptin-Deficiency Obese Mice. | 2019 | Details |
| A11536 | 30852481 | Pak J Pharm Sci | Clinical effect of the extract of TCM Fructus akebiae combined with ursodeoxycholic acid on nonalcoholic fatty liver disease. | 2019 | Details |
| A11553 | 30844893 | Curr Opin Gastroenterol | Current treatment options for nonalcoholic fatty liver disease. | 2019 | Details |
| A11693 | 30789804 | Int J Vitam Nutr Res | Liver Histological Improvement After Administration of High-Dose Vitamin C in Guinea Pig with Nonalcoholic Steatohepatitis. | 2019 | Details |
| A11955 | 30669332 | Nutrients | Spirulina Liquid Extract Protects against Fibrosis Related to Non-Alcoholic Steatohepatitis and Increases Ursodeoxycholic Acid. | 2019 | Details |
| A11995 | 30653687 | Hepatology | Deficiency of Mitochondrial Glycerol 3-Phosphate Dehydrogenase Contributes to Hepatic Steatosis. | 2019 | Details |
| A12368 | 30483564 | JGH Open | Non-alcoholic fatty liver disease in patients with autoimmune hepatitis. | 2018 | Details |
| A13613 | 29877264 | Intern Med | A Young Man with Non-alcoholic Steatohepatitis and Serum Anti-mitochondrial Antibody Positivity. | 2018 | Details |
| A14275 | 29488482 | Ter Arkh | [Optimization of therapy for hepatobiliary disorders in psoriatic patients]. | 2019 | Details |
| A14299 | 29475944 | J Biol Chem | Hepatic loss of Lissencephaly 1 (Lis1) induces fatty liver and accelerates liver tumorigenesis in mice. | 2018 | Details |
| A14694 | 29286519 | Probl Radiac Med Radiobiol | Comparative characteristics of hepatoprotectors used for the treatment of non alcoholic steatohepatitis associated with herpesvirus infection in sufferers of the Chornobyl accident. | 2017 | Details |
| A14850 | 29204050 | World J Gastroenterol | Current and emerging pharmacological therapy for non-alcoholic fatty liver disease. | 2017 | Details |
| A14904 | 29181663 | Bull Exp Biol Med | Gene TNF Polymorphism -308G>A (rs1800629) and Its Relationship with the Efficiency of Ursodeoxycholic Acid Therapy in Patients with Nonalcoholic Stetohepatitis. | 2017 | Details |
| A14985 | 29139555 | Br J Pharmacol | Tauroursodeoxycholic acid inhibits intestinal inflammation and barrier disruption in mice with non-alcoholic fatty liver disease. | 2018 | Details |
| A15539 | 28853202 | Liver Int | Ursodeoxycholic acid: Effects on hepatic unfolded protein response, apoptosis and oxidative stress in morbidly obese patients. | 2017 | Details |
| A15659 | 28777871 | Hepatology | A functional characteristic of cysteine-rich protein 61: Modulation of myeloid-derived suppressor cells in liver inflammation. | 2017 | Details |
| A15777 | 28714405 | Curr Pharm Des | Emerging Targets to Relieve Fat Stress-Induced Liver Diseases: UDCA, Tocotrienol, ω-3 PUFAs, and IgY Targeted NPC1L1 Cholesterol Transporter. | 2017 | Details |
| A16192 | 28511152 | Wiad Lek | [Pathogenetic substantiation of complex treatment of nonalcoholic steatohepatitis and steatosis in patients with pre-diabetes and type 2 diabetes]. | 2017 | Details |
| A16682 | 28249257 | Dig Dis | Therapeutic Mechanisms of Bile Acids and Nor-Ursodeoxycholic Acid in Non-Alcoholic Fatty Liver Disease. | 2017 | Details |
| A16939 | 28082803 | World J Gastroenterol | Liver fibrosis and hepatic stellate cells: Etiology, pathological hallmarks and therapeutic targets. | 2016 | Details |
| A17295 | 27859643 | Congenit Anom (Kyoto) | Undernourishment in utero and hepatic steatosis in later life: A potential issue in Japanese people. | 2017 | Details |
| A17462 | 27777888 | J Clin Transl Hepatol | Ursodeoxycholic Acid in Treatment of Non-cholestatic Liver Diseases: A Systematic Review. | 2016 | Details |
| A18175 | 27308649 | J Gastrointestin Liver Dis | Real-life Perception and Practice Patterns of NAFLD/NASH in Romania: Results of a Survey Completed by 102 Board-certified Gastroenterologists. | 2016 | Details |
| A18358 | 27184636 | Saudi J Gastroenterol | An open-label randomized control study to compare the efficacy of vitamin e versus ursodeoxycholic acid in nondiabetic and noncirrhotic Indian NAFLD patients. | 2017 | Details |
| A18539 | 27063274 | Clin Liver Dis | Current Pharmacologic Therapy for Nonalcoholic Fatty Liver Disease. | 2016 | Details |
| A18671 | 27003143 | Dig Dis Sci | Novel Pharmacotherapy Options for NASH. | 2016 | Details |
| A18691 | 26997458 | Int J Clin Pract | Efficacy and safety of ursodeoxycholic acid composite on fatigued patients with elevated liver function and/or fatty liver: a multi-centre, randomised, double-blinded, placebo-controlled trial. | 2016 | Details |
| A18692 | 26997214 | Saudi J Gastroenterol | Treatment of nonalcoholic fatty liver disease: Where do we stand? an overview. | 2017 | Details |
| A19020 | 26817117 | Eksp Klin Gastroenterol | [COMPARISON OF DIFFERENT TREATMENT REGIMENS IN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE]. | 2015 | Details |
| A19370 | 26601667 | J Gastroenterol | The intrahepatic expression levels of bile acid transporters are inversely correlated with the histological progression of nonalcoholic fatty liver disease. | 2015 | Details |
| A19473 | 26539645 | Oncotarget | Myristic acid potentiates palmitic acid-induced lipotoxicity and steatohepatitis associated with lipodystrophy by sustaning de novo ceramide synthesis. | 2015 | Details |
| A19745 | 26378648 | Semin Liver Dis | Pharmacotherapy for Nonalcoholic Fatty Liver Disease. | 2015 | Details |
| A20051 | 26190501 | J Gastroenterol | Beneficial effects of combined ursodeoxycholic acid and angiotensin-II type 1 receptor blocker on hepatic fibrogenesis in a rat model of nonalcoholic steatohepatitis. | 2015 | Details |
| A20134 | 26134756 | Pharm Biol | Protective effect of ursodeoxycholic acid, resveratrol, and N-acetylcysteine on nonalcoholic fatty liver disease in rats. | 2015 | Details |
| A20175 | 26108973 | Eur J Clin Invest | Ursodeoxycholyl Lysophosphatidylethanolamide modifies aberrant lipid profiles in NAFLD. | 2015 | Details |
| A20272 | 26052375 | World J Hepatol | Pathophysiological mechanisms involved in non-alcoholic steatohepatitis and novel potential therapeutic targets. | 2015 | Details |
| A20533 | 25906659 | Lik Sprava | [Optimization of long-term treatment with rosuvastatin of patients with myocardial infarction in combination with non-alcoholic steatohepatitis]. | 2015 | Details |
| A20794 | 25729888 | J Pediatr Gastroenterol Nutr | Serum Bile Acid Levels in Children With Nonalcoholic Fatty Liver Disease. | 2015 | Details |
| A20813 | 25716275 | Expert Rev Gastroenterol Hepatol | Management and diagnosis of fatty liver disease. | 2015 | Details |
| A20845 | 25690590 | Curr Atheroscler Rep | FXR agonists as therapeutic agents for non-alcoholic fatty liver disease. | 2015 | Details |
| A20959 | 25617503 | J Hepatol | Ursodeoxycholic acid exerts farnesoid X receptor-antagonistic effects on bile acid and lipid metabolism in morbid obesity. | 2015 | Details |
| A21067 | 27214981 | Eksp Klin Gastroenterol | [EFFICIENCY OF URSODEOXYCHOLIC ACID APPLICATION IN NONALCOCHOLIC STEATOHEPATITIS]. | 2015 | Details |
| A21108 | 25533429 | Eur J Gastroenterol Hepatol | Effects of ursodeoxycholic acid therapy on carotid intima media thickness, apolipoprotein A1, apolipoprotein B, and apolipoprotein B/A1 ratio in nonalcoholic steatohepatitis. | 2015 | Details |
| A21124 | 25528832 | Lik Sprava | [CORRECTION OF BILE FLOW CHARACTERISTICS IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE IN COMBINATION WITH HYPERURICEMIA]. | 2014 | Details |
| A21135 | 25523099 | Exp Mol Med | Omega-3 polyunsaturated fatty acid and ursodeoxycholic acid have an additive effect in attenuating diet-induced nonalcoholic steatohepatitis in mice. | 2014 | Details |
| A21289 | 25430494 | J Clin Pathol | Canals of Hering loss relates to the progression of the histological stages of primary biliary cirrhosis. | 2014 | Details |
| A21497 | 25274101 | Br J Nutr | Non-alcoholic fatty liver disease: need for a balanced nutritional source. | 2014 | Details |
| A21508 | 25267322 | Aliment Pharmacol Ther | Review article: the management of paediatric nonalcoholic fatty liver disease. | 2014 | Details |
| A21697 | 25111690 | Lab Invest | Uric acid induces fat accumulation via generation of endoplasmic reticulum stress and SREBP-1c activation in hepatocytes. | 2014 | Details |
| A21747 | 25073669 | Korean J Gastroenterol | [Comparison on the efficacy and safety of biphenyl dimethyl dicarboxylate and ursodeoxycholic acid in patients with abnormal alanine aminotransferase: multicenter, double-blinded, randomized, active-controlled clinical trial]. | 2014 | Details |
| A21876 | 24986741 | J Transl Med | Progression of diet induced nonalcoholic steatohepatitis is accompanied by increased expression of Kruppel-like-factor 10 in mice. | 2014 | Details |
| A22031 | 24865256 | Dig Dis Sci | Tauroursodeoxycholic acid attenuates progression of steatohepatitis in mice fed a methionine-choline-deficient diet. | 2014 | Details |
| A22050 | 24850606 | Georgian Med News | [Optimization of long-term hypolipidemia treatment of patients with myocardial infarction in combination with non-alcoholic steatohepatitis]. | 2014 | Details |
| A22106 | 24816727 | J Physiol Biochem | Bile acid supplementation improves established liver steatosis in obese mice independently of glucagon-like peptide-1 secretion. | 2014 | Details |
| A22175 | 24766485 | Clin Sci (Lond) | Endoplasmic reticulum stress does not contribute to steatohepatitis in obese and insulin-resistant high-fat-diet-fed foz/foz mice. | 2014 | Details |
| A22577 | 24448653 | Dig Dis Sci | A possible role of chenodeoxycholic acid and glycine-conjugated bile acids in fibrotic steatohepatitis in a dietary rat model. | 2014 | Details |
| A22610 | 24417071 | Klin Med (Mosk) | [Obesity and diseases of digestive organs]. | 2013 | Details |
| A22925 | 24206433 | Aliment Pharmacol Ther | Systematic review with meta-analysis: non-alcoholic steatohepatitis - a case for personalised treatment based on pathogenic targets. | 2013 | Details |
| A23085 | 24053454 | BMC Gastroenterol | The role of ursodeoxycholic acid in non-alcoholic steatohepatitis: a systematic review. | 2013 | Details |